Biocompatible osimertinib nanoliposomes coated with PEGylated hyaluronic acid enhanced tumor selectivity and cytotoxicity via CD44-mediated NSCLC targeting: Development, characterization and in-vitro biochemical studies

Sanjay Kumar Kuna Asha Deepti Choppala   

Open Access   

Published:  Mar 04, 2023

DOI: 10.7324/JAPS.2023.125444

Osimertinib (OMB) is an irreversible TK inhibitor approved to treat cancers with epidermal growth factor receptor (EGFR) mutations. Despite its high solubility and absorption, its poor tumor selectivity and off-target systemic toxicity pose problems to its effectiveness and safety. This study aimed to enhance tumor-targeted delivery of OMB via CD44 targeting by developing an effective OMB-nanoliposomal formulation for overcoming challenges associated with conventional OMB delivery. OMB-loaded liposomal formulations were developed using a freeze-drying method, and all were successfully characterized, including in-vitro OMB release. non-small cell lung cancer models H1975 and PC-9 cells were used to study hyaluronan-CD44 receptor targeting, cellular uptake, and cytotoxicity. All formulations exhibited superior characteristics of size, zeta potential, and PDI with high encapsulation efficiency. Among all formulations, mPEG-hyaluronic acid (HA) (mds)-OMB-LPs demonstrated long-term in-vitro drug release, with a cumulative % drug release of 99.99% ± 2.58% up to 72 hours stating the sustained release of OMB at pH 7.4. The cellular uptake and cytotoxicity of mPEG-HA coated LPs at a 1:1 was greater than those of OMB-LPs, as well as Tagrisso in both the cells overexpressing CD44, whereas the effect was lower in PC-9 cells having low CD44 expression. It is evident from these findings that successful liposomal formulations are taken up by cells via CD44-mediated processes. As compared with plain OMB solution, mPEG-HA-OMB-LPs increased in-vitro accumulation and cytotoxicity in both H1975 and PC-9 cells with activating EGFR mutations.

Keyword:     Osimertinib liposomes non-small cell lung cancer mPEG-HA coating EGFR


Kuna SK, Choppala AD. Biocompatible osimertinib nanoliposomes coated with PEGylated hyaluronic acid enhanced tumor selectivity and cytotoxicity via CD44- mediated NSCLC targeting: Development, characterization and in-vitro biochemical studies. J Appl Pharm Sci, 2023.

Copyright: © The Author(s). This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HTML Full Text


Andrews Wright NM, Goss GD. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Transl Lung Cancer Res, 2019; 8:247-64.

Brown K, Comisar C, Witjes H, Maringwa J, de Greef R, Vishwanathan K, Cantarini M, Cox E. Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer. Br J Clin Pharmacol, 2017; 83(6):1216-26.

Cancer Facts & Figures. American Cancer Society, 2022.

Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol, 2018; 11:64.

Chi Y, Yin X, Sun K, Feng S, Liu J, Chen D, Guo C, Wu Z. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models. J Control Release, 2017; 10(261):113-25.

Choi JH, Lee YJ, Kim DI. Image-guided nanomedicine for cancer. Int J Pharm Investig, 2016; 21(3):1-14.

Choi KY, Min KH, Yoon HY, Kim K, Park JH, Kwon IC, Choi K, Jeong SY. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials, 2011; 32(7):1880-9.

Gasperini AA, Puentes-Martinez XE, Balbino TA, Rigoletto Tde P, Corrêa Gde S, Cassago A, Portugal RV, de La Torre LG, Cavalcanti LP. Association between cationic liposomes and low molecular weight hyaluronic acid. Langmuir, 2015; 31:3308-17.

Grass GD, Tolliver LB, Bratoeva M, Toole BP. CD147, CD44, and the epidermal growth factor receptor (EGFR) signaling pathway cooperate to regulate breast epithelial cell invasiveness. J Biol Chem, 2013; 288:26089-104.

Hofheinz RD, Gnad Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anti Cancer Drugs, 2005; 16:691-707.

Inamura K, Ninomiya H, Ishikawa Y, Matsubara O. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features. Arch Pathol Lab Med, 2010; 134:66-72.

Ito T, Iida-Tanaka N, Koyama Y. Efficient in vivo gene transfection by stable DNA/PEI complexes coated by hyaluronic acid. J Drug Target, 2008; 16:276-81.

Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med, 2015; 372(18):1689-99.

Jeannot V, Gauche C, Mazzaferro S, Couvet M, Vanwonterghem L, Henry M, Didier C, Vollaire J, Josserand V, Coll JL, Schatz C, Lecommandoux S, Hurbin A. Anti-tumor efficacy of hyaluronan -based nanoparticles for the co-delivery of drugs in lung cancer. J Control Release, 2018; 275:117-28.

Jeannot V, Mazzaferro S, Lavaud J, Vanwonterghem L, Henry M, Arboléas M, Vollaire J, Josserand V, Coll JL, Lecommandoux S, Schatz C, Hurbin A. Targeting CD44 receptor -positive lung tumors using polysaccharide-based nanocarriers: influence of nanoparticle size and administration route. Nanomedicine, 2016; 12:921-32.

Kim JS. Liposomal drug delivery system. J Pharm Investig, 2016; 46:387-92.

Li C, Chen R, Xu M, Qiao J, Liang Y, Xin DG. Hyaluronic acid modified MPEG-b-PAE block copolymer aqueous micelles for efficient ophthalmic drug delivery of hydrophobic genistein. Drug Deliv, 2018; 25(1):1258-65.

Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Treat Rev, 2018; 65:1-10.

Moura J, Gonzaga A, Queiroz S, Martins MD, Pinto LP, Souza LB. Immunohistochemical expression of OCT4 and CD44 in major and minor salivary gland neoplasms. Braz Oral Res, 2021; 16(35):e073.

Ohsaki Y, Tanno S, Fujita Y, Toyoshima E, Fujiuchi S, Nishigaki Y, Ishida S, Nagase A, Miyokawa N, Hirata S, Kikuchi K. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep, 2000; 7:603-7.

Park NR, Cha JH, Jang JW, Bae SH, Jang B, Kim JH, Hur W, Choi JY, Yoon SK. Synergistic effects of CD44 and TGF-β1 through AKT/ GSK-3β/β-catenin signaling during epithelial-mesenchymal transition in liver cancer cells. Biochem Biophys Res Commun, 2016; 477:568-74.

Planchard D, Brown KH, Kim DW, Kim SW, Ohe Y, Felip E, Leese P, Cantarini M, Vishwanathan K, Jänne PA, Ranson M, Dickinson PA. Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for the formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother Pharmacol, 2016; 77(4):767-76.

Qhattal HS, Liu X. Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. Mol Pharm, 2011; 8:1233-46.

Rath B, Hochmair M, Plangger A, Hamilton G. Anticancer activity of fascaplysin against lung cancer cell and small cell lung cancer circulating tumor cell lines. Mar Drugs, 2018; 16(10):383.

Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res, 2004; 10:4227-32.

Shi S, Zhou M, Li X, Hu M, Li C, Li M, Sheng F, Li Z, Wu G, Luo M, Cui H, Li Z, Fu R, Xiang M, Xu J, Zhang Q, Lu L. Synergistic active targeting of dually integrin αvβ3/CD44 -targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies. J Control Release, 2016; 235:1-13.

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin, 2018; 68:7-30.

Takenaka T, Nakai S, Katayama M, Hirano M, Ueno N, Noguchi K, Takatani-Nakase T, Fujii I, Kobayashi SS, Nakase I. Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells. Int J Pharm. 2019; 15(572):118762.

Toole BP. Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res, 2009; 15:7462-68.

Toole BP, Slomiany MG. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol, 2008; 18:244-50.

Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov, 2005; 4:145-60.

Van VA, Van GR, Beer DY, Dingemans AM, Stolk L, Ter HR, Vries DF, Croes S. Validation of an analytical method using HPLC-MS/ MS to quantify osimertinib in human plasma and supplementary stability results. Biomed Chromatogr, 2020; 34(4):e4771.

Wobus M, Rangwala R, Sheyn I, Hennigan R, Coila B, Lower EE, Yassin RS, Sherman LS. CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells. Appl Immunohistochem Mol Morphol, 2002; 10:34-39.

Xu H, Wu K, Tian Y, Liu Q, Han N, Yuan X, Zhang L, Wu GS, Wu K. CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer. Int J Oncol, 2016; 49:1343-50.

Zaremba-Czogalla M, Jaromin A, Sidoryk K, Zagórska A, Cybulski M, Gubernator J. Evaluation of the in vitro cytotoxic activity of caffeic acid derivatives and liposomal formulation against pancreatic cancer cell lines. Materials (Basel), 2020; 13(24):5813.

Zhang Q, Deng C, Fu Y, Sun X, Gong T, Zhang Z. Repeated administration of hyaluronic acid coated liposomes with improved pharmacokinetics and reduced immune response. Mol Pharm, 2016; 13:1800-8.

Zhou B, Weigel JA, Fauss L, Weigel PH. Identification of the hyaluronan receptor for endocytosis (HARE). J Biol Chem, 2000; 275:37733-437741.

Article Metrics

0 Absract views 1 PDF Downloads 1 Total views

   Abstract      Pdf Download

Related Search

By author names

Citiaion Alert By Google Scholar

Name Required
Email Required Invalid Email Address

Comment required